
| SKU | A00128-4 |
|---|---|
| Application | Western blot |
| Sample | Rat MADB106 breast cancer cells |
| Sample Processing Description | Normally cultured MADB106 cells, MADB106 cells treated with an agonist, MADB106 cells treated with an inhibitor |
| Other Reagents | RIPA lysis buffer (Cat. No. AR0102, Bosterbio, Wuhan) Protease inhibitor, Running buffer, Transfer buffer, Blocking buffer |
| Primary Antibody | TRPV1 Antibody Picoband® |
| Primary Incubation | 1:2000, overnight at 4 ℃ |
| Secondary Antibody | 1:10,000, HRP-conjugated Goat Anti-Rabbit IgG |
| Secondary Incubation | 1h at 37℃ |
| Detection | Substrate: ECL substrate, Imaging system:ChemiDoc MP |
| Results Summary | The role of TRPV1 in breast cancer research is highly complex, varying with cell type, tumor subtype, and tumor microenvironment, and in some cases even showing contradictory effects. The current consensus is that TRPV1 is not only a potential therapeutic target for breast cancer but also an important prognostic and regulatory factor. Experimental results show that TRPV1 protein expression markedly increases in cells treated with an agonist, while it decreases in cells treated with an inhibitor. |










